An introduction to Continuous Glucose Monitoring

Continuous Glucose Monitoring (CGM) is a system that measures glucose levels continuously in order to monitor levels and allows the user to detect potential patterns throughout the day and night in real-time.

Unlike fingerprick tests, which provide a measurement for a single point in time, CGM provides dynamic glucose information by depicting trends and suggesting where one’s glucose levels may be heading. By using CGM, one could notice and respond to falling glucose levels before hypoglycaemia or monitor patterns while asleep.

Studies have shown the following benefits of CGM;

Significant improvement of HbA1C levels¹
Lowers the risk of hypoglycaemia^1,2
Increase time spent in range^1,3
Improvement in quality of life and well-being⁴

About Dexcom CGM :

Dexcom G7 is the latest technology in the Dexcom Continuous Glucose Monitoring (CGM) product line. The outstanding accuracy of Dexcom G7 allows you to make treatment decisions with no calibrations required, which means ZERO fingerpricks!^{^}

^{^} The Dexcom G7 system requires zero fingerpricks, however if your glucose alerts and readings from the G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Dexcom G7 CGM systems have 2 components:

Sensor – A slim all-in-one sensor continuously measures glucose levels just beneath the skin and sends data wirelessly to a display device
Display Device – A small touch screen receiver or your compatible smart device† displays real-time glucose data

Dexcom G6 CGM is also available for individuals living with diabetes. For more information on Dexcom G6, please click here.

In addition, real-time readings can also be seen by loved ones, friends or carers through the Dexcom Share feature, for added peace of mind!+

Dexcom CGM readings can be uploaded to web-based platforms Dexcom CLARITY or diasend^®by Glooko for later viewing. Data reports show patterns of low and high glucose events, time in range and more. Reports can also easily be shared with your healthcare team.

Contact us today on 0800 500 226 for more information on how Dexcom CGM could support your diabetes management!

Note: Dexcom G7 is not currently compatible with the t:slim X2 with Control-IQ technology. The teams at Dexcom and Tandem Diabetes Care are working hard to bring this update to customers, and as soon as we have an update here, we will let everyone know.

If you are using the t:slim X2 insulin pump with Control-IQ technology as part of your diabetes management plan and want to see your glucose values on your insulin pump, to ensure your pumping experience is not affected, we recommend continuing with Dexcom G6 for the time being. Alternatively, Dexcom G7 can also be used as a standalone system with a compatible display device.^†

Always read the label and use only as directed. Read the warnings available on nzmsdiabetes.co.nz/resources/ before purchasing. Consult your healthcare professional to see if this product is right for you.

^{^} The Dexcom G7 system requires zero fingerpricks, however if your glucose alerts and readings from the G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

^§ To receive readings from the Dexcom user, both Dexcom user and Dexcom follower needs a stable internet connection.

+Followers must separately download the Dexcom Follow App to view shared glucose information. A stable internet connection is needed to enable this Dexcom Share feature.

† For a full list of compatible display devices, please visit https://www.dexcom.com/compatibility. Display device sold separately.

*The Dexcom G7 Mobile transmitter can only be paired with one medical device and one compatible mobile device (phone or tablet) at the same time. To view a list of compatible smart devices, see here. The Dexcom G7 receiver cannot be used with the Dexcom G5 Mobile CGM system and vise versa.

References
1. Šoupal J, Petruželková L, Flekač M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538. doi:10.1089/dia.2016.0171 2. Welsh J, Gao P, Derdzinski M et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther. 2019;21(3):128-132. doi:10.1089/dia.2018.0374 3. Beck RW, et al. DIAMOND – JAMA. 2017. 4. Lind M, et al. GOLD JAMA. 2017.

Dexcom, Dexcom G7, Dexcom G6, Dexcom G5 Mobile, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.